JP2015524422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524422A5 JP2015524422A5 JP2015523550A JP2015523550A JP2015524422A5 JP 2015524422 A5 JP2015524422 A5 JP 2015524422A5 JP 2015523550 A JP2015523550 A JP 2015523550A JP 2015523550 A JP2015523550 A JP 2015523550A JP 2015524422 A5 JP2015524422 A5 JP 2015524422A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- polypeptide
- sequence set
- respect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 235000001014 amino acid Nutrition 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 238000006467 substitution reaction Methods 0.000 claims 17
- 241000725619 Dengue virus Species 0.000 claims 7
- 208000001490 Dengue Diseases 0.000 claims 6
- 206010012310 Dengue fever Diseases 0.000 claims 6
- 208000025729 dengue disease Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 230000002238 attenuated effect Effects 0.000 claims 3
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 3
- 241000710831 Flavivirus Species 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305908 | 2012-07-24 | ||
| EP12305908.1 | 2012-07-24 | ||
| EP12305911.5 | 2012-07-25 | ||
| EP12305911 | 2012-07-25 | ||
| PCT/EP2013/065669 WO2014016362A1 (en) | 2012-07-24 | 2013-07-24 | Vaccine compositions for prevention against dengue virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524422A JP2015524422A (ja) | 2015-08-24 |
| JP2015524422A5 true JP2015524422A5 (enExample) | 2016-09-08 |
Family
ID=48856641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015523550A Pending JP2015524422A (ja) | 2012-07-24 | 2013-07-24 | ワクチン組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150265695A1 (enExample) |
| EP (1) | EP2877207A1 (enExample) |
| JP (1) | JP2015524422A (enExample) |
| KR (1) | KR20150036593A (enExample) |
| CN (1) | CN104812408A (enExample) |
| AU (1) | AU2013295016A1 (enExample) |
| BR (1) | BR112015001313A2 (enExample) |
| CA (1) | CA2878599A1 (enExample) |
| GT (1) | GT201500005A (enExample) |
| HK (1) | HK1212905A1 (enExample) |
| MX (1) | MX2015000446A (enExample) |
| PE (1) | PE20150356A1 (enExample) |
| PH (1) | PH12014502875A1 (enExample) |
| SG (1) | SG11201500439RA (enExample) |
| WO (1) | WO2014016362A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3177572A1 (en) | 2013-03-15 | 2014-09-25 | Takeda Vaccines, Inc. | Compositions and methods for dengue virus chimeric constructs in vaccines |
| WO2014204892A1 (en) * | 2013-06-21 | 2014-12-24 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
| TWI852899B (zh) * | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| JP6942309B2 (ja) * | 2014-09-11 | 2021-09-29 | ブイエルピー・セラピューティクス・インコーポレイテッドＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | フラビウイルスウイルス様粒子 |
| MY192543A (en) | 2014-12-22 | 2022-08-26 | Merck Sharp & Dohme | Dengue virus vaccine compositions and methods of use thereof |
| EP3316905A1 (en) | 2015-07-03 | 2018-05-09 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| US10105434B2 (en) | 2015-08-03 | 2018-10-23 | The United States Of America As Represented By The Secretary Of The Navy | Immune enhancing recombinant dengue protein |
| PT3355915T (pt) * | 2015-09-29 | 2023-12-19 | Boehringer Ingelheim Animal Health Usa Inc | Vacinas de partículas pseudovirais (vlp) de parvovírus canino (cpv) e suas utilizações |
| US11531029B2 (en) | 2017-05-08 | 2022-12-20 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods and compositions for the detection of flavivirus infections |
| US11690903B2 (en) | 2017-10-05 | 2023-07-04 | Sanofi Pasteur | Compositions for booster vaccination against dengue |
| CN111556896A (zh) | 2017-12-21 | 2020-08-18 | 株式会社绿色生物医药 | 交叉免疫抗原疫苗及其制备方法 |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| KR20210071979A (ko) | 2018-09-05 | 2021-06-16 | 다케다 백신즈 인코포레이티드 | 뎅기열 백신 단위 용량 및 이의 투여 |
| BR112021022733A2 (pt) * | 2019-05-15 | 2022-02-01 | Codagenix Inc | Vírus da febre amarela atenuado e usos dos mesmos para o tratamento do câncer |
| CN120271718A (zh) * | 2024-01-05 | 2025-07-08 | 北京昌平实验室 | 针对寨卡/登革病毒的重组抗原、其疫苗组合物及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| FR2649013B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable |
| FR2649012B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Emulsions multiphasiques injectables |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
| AU6093296A (en) | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| DE69830579T2 (de) | 1997-02-28 | 2006-05-04 | Acambis, Inc., Cambridge | Chimäre impfstoffe gegen flaviviren |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| JP4426091B2 (ja) | 1997-09-05 | 2010-03-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニンを含有する水中油型エマルション |
| US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| US6511667B1 (en) | 1999-03-26 | 2003-01-28 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-2 virus vaccine |
| US6528065B1 (en) | 1999-03-26 | 2003-03-04 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-3 virus vaccine |
| AU4040400A (en) | 1999-03-26 | 2000-10-16 | Walter Reed Army Institute Of Research | Attenuated dengue-4 virus vaccine |
| CA2365728A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-1 virus vaccine |
| AU6514900A (en) * | 1999-08-02 | 2001-02-19 | Wyeth | Rescue of mumps virus from cdna |
| ATE526411T1 (de) | 2000-02-16 | 2011-10-15 | Us Gov Health & Human Serv | Avirulente, immunogene flavivirus-chimäre |
| ES2315221T3 (es) | 2000-05-30 | 2009-04-01 | Mahidol University | Cepas atenuadas del virus del dengue y su utilizacion en una composicion vaccinea. |
| AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
| JP2005518332A (ja) | 2001-05-23 | 2005-06-23 | デンドレオン コーポレイション | 細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用 |
| AU2002322026B2 (en) | 2001-06-01 | 2008-03-13 | Acambis Inc. | Chimeric flavivirus vectors |
| WO2003010197A2 (en) | 2001-07-25 | 2003-02-06 | Genset S.A. | Gmg-1 polynucleotides and polypeptides and uses thereof |
| ATE481982T1 (de) * | 2002-05-03 | 2010-10-15 | Us Gov Health & Human Serv | Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2. |
| AU2003239932A1 (en) | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| CN102010463A (zh) * | 2003-09-17 | 2011-04-13 | 杜克大学 | 共有/祖先免疫原 |
| JP5197362B2 (ja) * | 2005-06-17 | 2013-05-15 | サノフィ・パスツール | デング熱セロタイプ１弱毒株 |
| CA2611954C (en) * | 2005-06-17 | 2014-01-28 | Sanofi Pasteur | Dengue serotype 2 attenuated strain |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| EP1924280A4 (en) | 2005-08-10 | 2008-12-10 | Acambis Inc | VACCINATION AGAINST DENGUE VIRUS INFECTION |
| CU23586A1 (es) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| US7968102B2 (en) * | 2006-01-13 | 2011-06-28 | Sanofi Pasteur S.A. | Dengue chimeric viruses |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| EP2117589A4 (en) * | 2007-01-31 | 2010-07-21 | Sanofi Pasteur Biologics Co | FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS |
| BRPI0913012B1 (pt) * | 2008-04-30 | 2021-12-14 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Quimera de ácido nucleico, métodos para detectar um anticorpo do vírus da dengue em uma amostra de um paciente, e para produzir partículas virais que expressam proteínas prm e e do vírus da dengue, uso de vírus codificado pela quimera e flavivírus ou partícula viral quiméricos |
| EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| JP2013500329A (ja) * | 2009-07-29 | 2013-01-07 | ヘルムート アダム レフム ベルン | ポリマー粒子およびその使用 |
| US8900596B2 (en) * | 2009-11-18 | 2014-12-02 | The Board Of Regents Of The University Of Texas System | Physicochemical (PCP) based consensus sequences and uses thereof |
| GB201007531D0 (en) | 2010-05-05 | 2010-06-23 | Imp Innovations Ltd | Composition |
| CN102906266A (zh) * | 2010-05-21 | 2013-01-30 | 高等教育联邦系统-匹兹堡大学 | 登革病毒通用序列及其使用方法 |
| WO2012051491A1 (en) * | 2010-10-14 | 2012-04-19 | The United States Of America, As Represented By The Secretary National Institutes Of Health | Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting |
| JP2015524421A (ja) * | 2012-07-24 | 2015-08-24 | サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ | ワクチン組成物 |
-
2013
- 2013-07-24 US US14/416,492 patent/US20150265695A1/en not_active Abandoned
- 2013-07-24 SG SG11201500439RA patent/SG11201500439RA/en unknown
- 2013-07-24 EP EP13740025.5A patent/EP2877207A1/en not_active Withdrawn
- 2013-07-24 PE PE2015000070A patent/PE20150356A1/es not_active Application Discontinuation
- 2013-07-24 CA CA2878599A patent/CA2878599A1/en not_active Abandoned
- 2013-07-24 BR BR112015001313A patent/BR112015001313A2/pt not_active IP Right Cessation
- 2013-07-24 KR KR20157003822A patent/KR20150036593A/ko not_active Withdrawn
- 2013-07-24 JP JP2015523550A patent/JP2015524422A/ja active Pending
- 2013-07-24 CN CN201380049741.2A patent/CN104812408A/zh active Pending
- 2013-07-24 AU AU2013295016A patent/AU2013295016A1/en not_active Abandoned
- 2013-07-24 WO PCT/EP2013/065669 patent/WO2014016362A1/en not_active Ceased
- 2013-07-24 HK HK16100914.5A patent/HK1212905A1/zh unknown
- 2013-07-24 MX MX2015000446A patent/MX2015000446A/es unknown
-
2014
- 2014-12-23 PH PH12014502875A patent/PH12014502875A1/en unknown
-
2015
- 2015-01-12 GT GT201500005A patent/GT201500005A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524422A5 (enExample) | ||
| CY1124202T1 (el) | Εμβολια ανασυνδυασμενου zika | |
| JP2014502156A5 (enExample) | ||
| WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
| EP3199545A3 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
| JP2014000092A5 (enExample) | ||
| WO2012106377A3 (en) | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof | |
| JP2017526689A5 (enExample) | ||
| JP2013517773A5 (enExample) | ||
| WO2017015463A3 (en) | Infectious disease vaccines | |
| JP2015524421A5 (enExample) | ||
| HK1208355A1 (en) | Universal influenza vaccine based on heterologous multiple m2e proteins | |
| JP2015533841A5 (enExample) | ||
| JP2014534202A5 (enExample) | ||
| JP2014530010A5 (enExample) | ||
| RU2015135890A (ru) | Композиция вакцины | |
| JP2011530309A5 (enExample) | ||
| WO2010057159A3 (en) | Antigens that elicit immune response against flavivirus and methods of using same | |
| JP2016533332A5 (enExample) | ||
| PH12015500499A1 (en) | Recombinant measles virus expressing chikungunya virus polypeptides and their applications | |
| RU2015138530A (ru) | Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| HK1203524A1 (en) | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses | |
| MX343830B (es) | Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma. | |
| JP2018531624A5 (enExample) |